Skip to content

US · DBVT · BIOTECHNOLOGY

DBV Technologies S.A. (DBVT) intrinsic value and stock valuation

$9.02as of 2026-11-21 · Mkt cap 340.65M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

DBV Technologies S.A. DCF and intrinsic value

InvestorsCraft values DBVT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DBVT’s statements →

DBV Technologies S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Châtillon 92320 dbv-technologies.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-146.95M
20112025
Free cash flow
-$-121.18M
20112025
Total equity
$168.8M-3.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$15.7M$4.84M$5.71M
Operating income-$-147.06M-$-120.53M-$-76.43M-$-96.63M-$-98.61M
Net income-$-146.95M-$-113.72M-$-72.73M-$-96.27M-$-97.81M
EPSd-$-1.7M-$-1.18M-$-764.61K-$-1.24M-$-1.78M
Operating cash flow-$-121.18M-$-104.47M-$-79.65M-$-55.7M-$-108.24M
Capital expenditure-$-530K-$-2.34M-$-680K-$-750K-$-920K
Free cash flow-$-121.18M-$-106.81M-$-80.33M-$-56.45M-$-109.16M
Total assets$233.7M$65.7M$183M$246.5M$146.3M
Total debt$21.7M$7.8M$6.55M$10M$10.7M
Net debt-$-172.48M-$-24.66M-$-134.81M-$-199.17M-$-66.64M
Total equity$168.8M$27.4M$140.2M$194.5M$99M
Cash and short-term investments$194.2M$32.5M$141.4M$209.2M$77.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$15.7M$4.84M$5.71M
Cost of revenue$0.00$6.81M$0.00$0.00$10.4M
Gross profit$0.00-$-6.81M$15.7M$4.84M-$-4.68M
Research and development expenses$116.7M$89.9M$60.2M$75.5M$70.3M
Selling, general and administrative expenses$36M$23.8M$31.9M$25.9M$23.8M
Other expenses-$-5.64M$0.00-$0.00$0.00-$-230K
Operating expenses$147.1M$113.7M$92.2M$101.5M$93.9M
Cost and expenses$147.1M$120.5M$92.2M$101.5M$104.3M
Interest income$600K$2.73M$3.71M$430K$520K
Interest expense$0.00$0.00$0.00$0.00$690K
Depreciation and amortization$7.73M$6.81M$13.2M$13.2M$8.38M
Ebitda-$-139.32M-$-110.99M-$-63.27M-$-83.47M-$-91.16M
Operating income-$-147.06M-$-120.53M-$-76.43M-$-96.63M-$-98.61M
Total other income/expenses, net$600K$2.73M$3.71M$430K$420K
Income before tax-$-146.46M-$-117.8M-$-72.72M-$-96.2M-$-98.19M
Income tax expense$490K-$-4.08M$10K$70K-$-380K
Net income-$-146.95M-$-113.72M-$-72.73M-$-96.27M-$-97.81M
Weighted average shares outstanding$86.4M$96.2M$95.1M$77.4M$55.1M
Weighted average diluted shares outstanding$86.4M$96.2M$95.1M$77.4M$55.1M
Balance sheet
20252024202320222021
Cash and short-term investments$194.2M$32.5M$141.4M$209.2M$77.3M
Net receivables$16.2M$10.4M$15.5M$11.2M$33.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$212.9M$44.4M$158.9M$223.1M$114.5M
Property, plant and equipment, net$15M$16.8M$17.9M$17.6M$24.9M
Goodwill and intangible assets$20K$40K$60K$10K$20K
Long-term investments$620K$4.31M$3.68M$4.05M$3.97M
Total non-current assets$20.8M$21.3M$24.1M$23.4M$31.8M
Total assets$233.7M$65.7M$183M$246.5M$146.3M
Accounts payable$40.9M$22M$23.3M$14.5M$11.4M
Short-term debt$16.3M$1.5M$2.03M$8.9M$3.51M
Deferred revenue$0.00$0.00$0.00$2.14M$4.15M
Total current liabilities$58M$31.1M$37.3M$29.5M$31.4M
Long-term debt$5.41M$6.3M$4.53M$1.13M$7.15M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$6.92M$7.13M$5.46M$22.5M$15.9M
Capital lease obligations$5.41M$6.95M$5.67M$1.13M$7.15M
Total liabilities$65M$38.3M$42.8M$52.1M$47.3M
Common stock$26.1M$11.7M$11M$10.7M$6.54M
Retained earnings-$-393.13M-$-286.38M-$-238.86M-$-259.58M-$-98.05M
Accumulated other comprehensive income (loss)-$-5.43M-$-12.19M-$-8.13M-$-13.8M-$-15.39M
Total equity$168.8M$27.4M$140.2M$194.5M$99M
Total investments$620K$4.31M$3.68M$4.05M$3.97M
Total debt$21.7M$7.8M$6.55M$10M$10.7M
Net debt-$-172.48M-$-24.66M-$-134.81M-$-199.17M-$-66.64M
Cash flow statement
20252024202320222021
Net income-$-146.95M-$-113.92M-$-72.73M-$-96.27M-$-97.81M
Depreciation and amortization$3.19M-$-930K-$-14M$13.2M$8.38M
Stock-based compensation$5.39M$4.62M$6.02M$5.03M$3.12M
Change in working capital$1.34M$5.75M$950K$22.3M-$-22.77M
Accounts receivable$0.00$0.00$0.00$0.00$2.15M
Inventory-$-16.11M$0.00$0.00$0.00-$-16.18M
Accounts payable$15.8M$270K$8.42M$3.46M-$-7.56M
Net cash provided by operating activities-$-121.18M-$-104.47M-$-79.65M-$-55.7M-$-108.24M
Investments in property, plant and equipment-$-540K-$-2.34M-$-680K-$-750K-$-920K
Acquisitions, net$0.00$0.00$0.00$10K$510K
Net cash used for investing activities-$-1.37M-$-760K-$-810K-$-100K-$-430K
Common stock issued$277M$630K$6.92M$194.6M$980K
Common stock repurchased$0.00-$-50K-$-150K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$276.2M$590K$6.77M$194.1M$270K
Net change in cash$161.7M-$-108.91M-$-67.83M$131.9M-$-119.05M
Cash at end of period$194.2M$32.5M$141.4M$209.2M$77.3M
Operating cash flow-$-121.18M-$-104.47M-$-79.65M-$-55.7M-$-108.24M
Capital expenditure-$-530K-$-2.34M-$-680K-$-750K-$-920K
Free cash flow-$-121.18M-$-106.81M-$-80.33M-$-56.45M-$-109.16M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About DBV Technologies S.A.

        DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

        CEO
        Daniel Tassé
        Employees
        161
        Beta
        -0.21

        Explore

        Frequently asked questions

        What is the intrinsic value of DBV Technologies S.A. (DBVT)?

        InvestorsCraft does not currently publish an intrinsic value for DBVT. How the IC value is calculated.

        Is DBVT undervalued?

        InvestorsCraft does not publish an undervaluation signal for DBVT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.